LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX)

Q: What does CUSIP 528872302 represent in this 13F holders report?

CUSIP 528872302 is the security identifier for LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in Q4 2025?

122 institutional investors reported LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 528872302

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 444,558,533
Total 13F shares: 260,415,048
Share change: +4,519,522
Total reported value: $299,475,172
Put/Call ratio: 28%
Price per share: $1.15
Number of holders: 122
Value change: +$5,062,350
Number of buys: 47
Number of sells: 57

Quarterly Holders Quick Answers

What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 528872302:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Artal Group S.A.	13F	Company	31%	136,180,481	$183,843,649	—	30 Sep 2025	13F
Siren, L.L.C.	3/4/5 13F	Director, 10%+ Owner · Individual	8.8% from 13F	35,402,689	$92,755,045	—	25 Jul 2024	3/4/5 13F
FMR LLC	13F 13D/G	Company	10% from 13D/G	38,679,748	$52,217,659	—	30 Sep 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	2.1%	9,521,874	$12,854,530	—	30 Sep 2025	13F
Invus US Partners LLC	3/4/5	Director, 10%+ Owner	— class O/S missing	5,782,749	$6,090,969	—	05 Aug 2022	3/4/5
MILLENNIUM MANAGEMENT LLC	13F	Company	0.86%	3,830,660	$5,171,391	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	0.76%	3,394,972	$4,583,212	—	30 Sep 2025	13F
Sessa Capital IM, L.P.	13F	Company	0.67%	3,000,000	$4,050,000	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.59%	2,634,027	$3,555,936	—	30 Sep 2025	13F
Lonnel Coats	3/4/5	Chief Executive Officer, Director	— mixed-class rows	2,109,255 mixed-class rows	$3,507,748	—	28 Feb 2024	3/4/5
CIBC Private Wealth Group LLC	13F	Company	0.54%	2,400,257	$3,240,347	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.54%	2,397,923	$3,238,240	—	30 Sep 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.27%	1,202,906	$1,624,000	—	30 Sep 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.26%	1,144,632	$1,545,253	—	30 Sep 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.22%	962,060	$1,298,781	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.2%	880,121	$1,188,163	—	30 Sep 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.19%	825,633	$1,114,603	—	30 Sep 2025	13F
Jeffrey L. Wade	3/4/5	President and COO	— mixed-class rows	729,441 mixed-class rows	$1,106,796	—	08 Jul 2024	3/4/5
Hennion & Walsh Asset Management, Inc.	13F	Company	0.18%	779,212	$1,051,936	—	30 Sep 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.16%	722,183	$975,000	—	30 Sep 2025	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.16%	692,727	$935,181	—	30 Sep 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.13%	559,008	$754,661	—	30 Sep 2025	13F
Invesco Ltd.	13F	Company	0.12%	521,403	$703,894	—	30 Sep 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.1%	456,530	$616,315	—	30 Sep 2025	13F
B. Kassler Taub	3/4/5	SVP, Regulatory & QA	— mixed-class rows	431,995 mixed-class rows	$597,845	—	28 Feb 2024	3/4/5
Lombard Odier SCmA Compagnie	13F	Individual	0.09%	410,000	$553,500	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.08%	369,794	$499,222	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0.08%	352,922	$476,445	—	30 Sep 2025	13F
Monaco Asset Management SAM	13F	Company	0.08%	350,000	$472,500	—	30 Sep 2025	13F
XTX Topco Ltd	13F	Company	0.07%	329,536	$444,874	—	30 Sep 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.07%	302,931	$408,957	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.07%	292,400	$394,740	—	30 Sep 2025	13F
Ph.D. Alan J. Main	3/4/5	EVP, Innov & Chem Sciences	— mixed-class rows	1,228,681 mixed-class rows	$318,646	—	28 Feb 2025	3/4/5
Quadrature Capital Ltd	13F	Company	0.05%	228,209	$309,223	—	30 Sep 2025	13F
Brian T. Corrigan	3/4/5	SVP, Regulatory & QA	— mixed-class rows	1,121,660 mixed-class rows	$300,602	—	13 Feb 2025	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.05%	216,244	$291,929	—	30 Sep 2025	13F
Thomas Garner	3/4/5	SVP, Chief Commercial Officer	— mixed-class rows	454,260 mixed-class rows	$239,236	—	08 Feb 2024	3/4/5
Ikarian Capital, LLC	13F	Company	0.04%	176,479	$238,247	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0.04%	169,018	$228,175	—	30 Sep 2025	13F
Robert J. Lefkowitz MD	3/4/5	Director	— mixed-class rows	130,080 mixed-class rows	$223,156	—	13 May 2024	3/4/5
Cerity Partners LLC	13F	Company	0.04%	158,040	$213,354	—	30 Sep 2025	13F
Jefferies Financial Group Inc.	13F	Company	0.02%	97,400	$131,490	—	30 Sep 2025	13F
LPL Financial LLC	13F	Company	0.02%	91,258	$123,198	—	30 Sep 2025	13F
Ph.D. Kiernan Seth	3/4/5	VP, Chief Commercial Officer	— mixed-class rows	379,163 mixed-class rows	$104,343	—	28 Feb 2023	3/4/5
Optiver Holding B.V.	13F	Company	0.02%	75,893	$102,456	—	30 Sep 2025	13F
SIMPLEX TRADING, LLC	13F	Company	0.02%	73,287	$98,000	—	30 Sep 2025	13F
BANK OF MONTREAL /CAN/	13F	Company	0.02%	70,000	$94,500	—	30 Sep 2025	13F
Vanguard Personalized Indexing Management, LLC	13F	Company	0.01%	66,567	$89,865	—	30 Sep 2025	13F
China Universal Asset Management Co., Ltd.	13F	Company	0.01%	63,698	$85,992	—	30 Sep 2025	13F
Cubist Systematic Strategies, LLC	13F	Company	0.01%	63,484	$85,704	—	30 Sep 2025	13F

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) as of Q4 2025

As of 31 Dec 2025, LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) was held by 122 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 260,415,048 shares. The largest 10 holders included Artal Group S.A., Siren, L.L.C., FMR LLC, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, BlackRock, Inc., UBS Group AG, Sessa Capital IM, L.P., GEODE CAPITAL MANAGEMENT, LLC, and CIBC Private Wealth Group LLC. This page lists 122 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

121

Q4 2025 holders

122

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.